{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:11:07Z","timestamp":1791443467029,"version":"4.3.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,7,14]],"date-time":"2017-07-14T00:00:00Z","timestamp":1499990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,7,14]],"date-time":"2017-07-14T00:00:00Z","timestamp":1499990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with moyamoya disease (MMD) or intracranial atherosclerotic disease (ICAD) experience similar cerebral ischaemic events. However, MMD patients show greater angiogenesis and arteriogenesis, which play crucial roles in collateral circulation development to enhance clinical prognosis and outcome. Apelins have been associated with angiogenesis and arteriogenesis. Therefore, the aim of the present study was to determine whether apelin levels were higher in patients with MMD than in patients with ICAD or in healthy controls. We compared plasma apelin levels in 29 patients with MMD, 82 patients with ICAD, and 25 healthy participants. Twelve-hour fasting blood samples were collected and analysed using commercially available kits. Univariate analyses indicated that compared with the ICAD and healthy control groups, the MMD group had higher apelin-12, apelin-13, apelin-36, and nitric oxide levels. Binary logistic regression analyses further showed that the plasma apelin-12 level was substantially higher in MMD patients than in ICAD patients. Patients with MMD were also differentiated from patients with ICAD by their mean ages, with the former being younger. Therefore, the plasma apelin-12 level is a potential diagnostic marker for differentiating MMD and ICAD and may provide a treatment strategy for enhancing collateral circulation development and clinical prognosis and outcome.<\/jats:p>","DOI":"10.1038\/s41598-017-05664-8","type":"journal-article","created":{"date-parts":[[2017,7,10]],"date-time":"2017-07-10T11:29:47Z","timestamp":1499686187000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prospective evaluation of the diagnostic value of plasma apelin 12 levels for differentiating patients with moyamoya and intracranial atherosclerotic diseases"],"prefix":"10.1038","volume":"7","author":[{"given":"Wei","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanghua","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,14]]},"reference":[{"key":"5664_CR1","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3340\/jkns.2015.57.6.408","volume":"57","author":"JH Phi","year":"2015","unstructured":"Phi, J. H., Wang, K. C., Lee, J. Y. & Kim, S. K. Moyamoya Syndrome: A Window of Moyamoya Disease. J Korean Neurosurg Soc \n                           57, 408\u2013414, doi:10.3340\/jkns.2015.57.6.408 (2015).","journal-title":"J Korean Neurosurg Soc"},{"key":"5664_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jocn.2015.12.042","volume":"32","author":"JH Cheng","year":"2016","unstructured":"Cheng, J. H., Ye, Q., Ye, Z. S., Li, Z. Q. & Xu, A. D. Five-year experience of 101 adult patients with moyamoya disease at a single institution in Eastern China. J Clin Neurosci \n                           32, 30\u201334, doi:10.1016\/j.jocn.2015.12.042 (2016).","journal-title":"J Clin Neurosci"},{"key":"5664_CR3","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1056\/NEJMc0904160","volume":"361","author":"RM Scott","year":"2009","unstructured":"Scott, R. M. & Smith, E. R. Moyamoya Disease and Moyamoya Syndrome REPLY. New Engl J Med \n                           361, 98\u201398 (2009).","journal-title":"New Engl J Med"},{"key":"5664_CR4","doi-asserted-by":"publisher","first-page":"345","DOI":"10.2176\/nmc.oa.2016-0031","volume":"56","author":"Y Takagi","year":"2016","unstructured":"Takagi, Y. et al. Histopathological Characteristics of Distal Middle Cerebral Artery in Adult and Pediatric Patients with Moyamoya Disease. Neurol Med-Chir \n                           56, 345\u2013349, doi:10.2176\/nmc.oa.2016-0031 (2016).","journal-title":"Neurol Med-Chir"},{"key":"5664_CR5","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1161\/STROKEAHA.108.529420","volume":"40","author":"N Rafat","year":"2009","unstructured":"Rafat, N., Beck, G., Pena-Tapia, P. G., Schmiedek, P. & Vajkoczy, P. Increased levels of circulating endothelial progenitor cells in patients with Moyamoya disease. Stroke \n                           40, 432\u2013438, doi:10.1161\/STROKEAHA.108.529420 (2009).","journal-title":"Stroke"},{"key":"5664_CR6","doi-asserted-by":"publisher","first-page":"7692","DOI":"10.1038\/sj.onc.1210573","volume":"26","author":"SC Sorli","year":"2007","unstructured":"Sorli, S. C., Le Gonidec, S., Knibiehler, B. & Audigier, Y. Apelin is a potent activator of tumour neoangiogenesis. Oncogene \n                           26, 7692\u20137699, doi:10.1038\/sj.onc.1210573 (2007).","journal-title":"Oncogene"},{"key":"5664_CR7","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/sj.emboj.7601982","volume":"27","author":"H Kidoya","year":"2008","unstructured":"Kidoya, H. et al. Spatial and temporal role of the apelin\/APJ system in the caliber size regulation of blood vessels during angiogenesis. Embo J \n                           27, 522\u2013534, doi:10.1038\/sj.emboj.7601982 (2008).","journal-title":"Embo J"},{"key":"5664_CR8","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.atherosclerosis.2014.04.029","volume":"235","author":"MK Akboga","year":"2014","unstructured":"Akboga, M. K. et al. Relationship between plasma apelin level and coronary collateral circulation. Atherosclerosis \n                           235, 289\u2013294, doi:10.1016\/j.atherosclerosis.2014.04.029 (2014).","journal-title":"Atherosclerosis"},{"key":"5664_CR9","doi-asserted-by":"publisher","unstructured":"Chen, D. D., Lee, J. W., Gu, X. H., Wei, L. & Yu, S. P. Intranasal Delivery of Apelin-13 Is Neuroprotective and Promotes Angiogenesis After Ischemic Stroke in Mice. Asn Neuro \n                           7, doi:10.1177\/1759091415605114 (2015).","DOI":"10.1177\/1759091415605114"},{"key":"5664_CR10","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1006\/bbrc.1998.9489","volume":"251","author":"K Tatemoto","year":"1998","unstructured":"Tatemoto, K. et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun \n                           251, 471\u2013476, doi:10.1006\/bbrc.1998.9489 (1998).","journal-title":"Biochem Biophys Res Commun"},{"key":"5664_CR11","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s10741-015-9475-x","volume":"20","author":"A Folino","year":"2015","unstructured":"Folino, A., Montarolo, P. G., Samaja, M. & Rastaldo, R. Effects of apelin on the cardiovascular system. Heart Fail Rev \n                           20, 505\u2013518, doi:10.1007\/s10741-015-9475-x (2015).","journal-title":"Heart Fail Rev"},{"key":"5664_CR12","doi-asserted-by":"crossref","unstructured":"Tatemoto, K. et al. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept \n                           99, 87\u201392, doi:S0167011501002361 [pii] (2001).","DOI":"10.1016\/S0167-0115(01)00236-1"},{"key":"5664_CR13","first-page":"307","volume":"23","author":"Y Suzuki","year":"2000","unstructured":"Suzuki, Y. et al. Role of nitric oxide in the control of cerebral microcirculation under physiological and pathological conditions. Clin Hemorheol Microcirc \n                           23, 307\u2013312 (2000).","journal-title":"Clin Hemorheol Microcirc"},{"key":"5664_CR14","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.cca.2016.12.023","volume":"466","author":"L Wu","year":"2017","unstructured":"Wu, L., Chen, L. & Li, L. Apelin\/APJ system: A novel promising therapy target for pathological angiogenesis. Clin Chim Acta \n                           466, 78\u201384, doi:10.1016\/j.cca.2016.12.023 (2017).","journal-title":"Clin Chim Acta"},{"key":"5664_CR15","doi-asserted-by":"publisher","first-page":"e000249","DOI":"10.1161\/JAHA.113.000249","volume":"2","author":"W Wang","year":"2013","unstructured":"Wang, W. et al. Loss of Apelin exacerbates myocardial infarction adverse remodeling and ischemia-reperfusion injury: therapeutic potential of synthetic Apelin analogues. J Am Heart Assoc \n                           2, e000249, doi:10.1161\/JAHA.113.000249 (2013).","journal-title":"J Am Heart Assoc"},{"key":"5664_CR16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/jcmm.12453","volume":"19","author":"X Hou","year":"2015","unstructured":"Hou, X., Zeng, H., He, X. & Chen, J. X. Sirt3 is essential for apelin-induced angiogenesis in post-myocardial infarction of diabetes. J Cell Mol Med \n                           19, 53\u201361, doi:10.1111\/jcmm.12453 (2015).","journal-title":"J Cell Mol Med"},{"key":"5664_CR17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ejphar.2015.04.034","volume":"761","author":"Y Azizi","year":"2015","unstructured":"Azizi, Y. et al. Post-infarct treatment with [Pyr(1)]apelin-13 improves myocardial function by increasing neovascularization and overexpression of angiogenic growth factors in rats. Eur J Pharmacol \n                           761, 101\u2013108, doi:10.1016\/j.ejphar.2015.04.034 (2015).","journal-title":"Eur J Pharmacol"},{"key":"5664_CR18","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00380-013-0425-z","volume":"29","author":"BH Zhang","year":"2014","unstructured":"Zhang, B. H. et al. Cardioprotective effects of adipokine apelin on myocardial infarction. Heart Vessels \n                           29, 679\u2013689, doi:10.1007\/s00380-013-0425-z (2014).","journal-title":"Heart Vessels"},{"key":"5664_CR19","doi-asserted-by":"publisher","unstructured":"Chen, D., Lee, J., Gu, X., Wei, L. & Yu, S. P. Intranasal Delivery of Apelin-13 Is Neuroprotective and Promotes Angiogenesis After Ischemic Stroke in Mice. ASN Neuro \n                           7, doi:10.1177\/1759091415605114 (2015).","DOI":"10.1177\/1759091415605114"},{"key":"5664_CR20","doi-asserted-by":"publisher","first-page":"H585","DOI":"10.1152\/ajpheart.00821.2013","volume":"306","author":"H Zeng","year":"2014","unstructured":"Zeng, H., He, X., Hou, X., Li, L. & Chen, J. X. Apelin gene therapy increases myocardial vascular density and ameliorates diabetic cardiomyopathy via upregulation of sirtuin 3. Am J Physiol Heart Circ Physiol \n                           306, H585\u2013597, doi:10.1152\/ajpheart.00821.2013 (2014).","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"5664_CR21","doi-asserted-by":"publisher","first-page":"e60457","DOI":"10.1371\/journal.pone.0060457","volume":"8","author":"BH Zhang","year":"2013","unstructured":"Zhang, B. H., Wang, W., Wang, H., Yin, J. & Zeng, X. J. Promoting effects of the adipokine, apelin, on diabetic nephropathy. PLoS One \n                           8, e60457, doi:10.1371\/journal.pone.0060457 (2013).","journal-title":"PLoS One"},{"key":"5664_CR22","doi-asserted-by":"publisher","unstructured":"Hiramatsu, M. et al. Combined gene therapy with vascular endothelial growth factor plus apelin in a chronic cerebral hypoperfusion model in rats. J Neurosurg. 1\u20138, doi:10.3171\/2016.8.JNS16366 (2016).","DOI":"10.3171\/2016.8.JNS16366"},{"key":"5664_CR23","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.03.032","volume":"24","author":"J Li","year":"2015","unstructured":"Li, J. et al. Human Urinary Kallidinogenase Improves Outcome of Stroke Patients by Shortening Mean Transit Time of Perfusion Magnetic Resonance Imaging. J Stroke Cerebrovasc Dis \n                           24, 1730\u20131737, doi:10.1016\/j.jstrokecerebrovasdis.2015.03.032 (2015).","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"5664_CR24","doi-asserted-by":"publisher","first-page":"e0134543","DOI":"10.1371\/journal.pone.0134543","volume":"10","author":"L Han","year":"2015","unstructured":"Han, L. et al. Human Urinary Kallidinogenase Promotes Angiogenesis and Cerebral Perfusion in Experimental Stroke. PLoS One \n                           10, e0134543, doi:10.1371\/journal.pone.0134543 (2015).","journal-title":"PLoS One"},{"key":"5664_CR25","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.1182\/blood-2009-07-232306","volume":"115","author":"H Kidoya","year":"2010","unstructured":"Kidoya, H., Naito, H. & Takakura, N. Apelin induces enlarged and nonleaky blood vessels for functional recovery from ischemia. Blood \n                           115, 3166\u20133174, doi:10.1182\/blood-2009-07-232306 (2010).","journal-title":"Blood"},{"key":"5664_CR26","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.biomaterials.2015.10.062","volume":"76","author":"JS Park","year":"2016","unstructured":"Park, J. S., Yang, H. N., Yi, S. W., Kim, J. H. & Park, K. H. Neoangiogenesis of human mesenchymal stem cells transfected with peptide-loaded and gene-coated PLGA nanoparticles. Biomaterials \n                           76, 226\u2013237, doi:10.1016\/j.biomaterials.2015.10.062 (2016).","journal-title":"Biomaterials"},{"key":"5664_CR27","first-page":"1122","volume":"20","author":"Q Lu","year":"2014","unstructured":"Lu, Q., Ma, Y., Xu, Y. S. & Jiang, Y. R. Apelin in epiretinal membranes of patients with proliferative diabetic retinopathy. Mol Vis \n                           20, 1122\u20131131 (2014).","journal-title":"Mol Vis"},{"key":"5664_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cca.2013.09.001","volume":"428","author":"XH Yu","year":"2014","unstructured":"Yu, X. H. et al. Apelin and its receptor APJ in cardiovascular diseases. Clin Chim Acta \n                           428, 1\u20138, doi:10.1016\/j.cca.2013.09.001 (2014).","journal-title":"Clin Chim Acta"},{"key":"5664_CR29","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.peptides.2012.07.012","volume":"37","author":"B Cheng","year":"2012","unstructured":"Cheng, B., Chen, J., Bai, B. & Xin, Q. Neuroprotection of apelin and its signaling pathway. Peptides \n                           37, 171\u2013173, doi:10.1016\/j.peptides.2012.07.012 (2012).","journal-title":"Peptides"},{"key":"5664_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnmol.2017.00001","volume":"10","author":"Y Wu","year":"2017","unstructured":"Wu, Y. et al. Temporal Expression of Apelin\/Apelin Receptor in Ischemic Stroke and its Therapeutic Potential. Front Mol Neurosci \n                           10, 1, doi:10.3389\/fnmol.2017.00001 (2017).","journal-title":"Front Mol Neurosci"},{"key":"5664_CR31","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.cca.2015.09.029","volume":"451","author":"L He","year":"2015","unstructured":"He, L., Xu, J., Chen, L. & Li, L. Apelin\/APJ signaling in hypoxia-related diseases. Clin Chim Acta \n                           451, 191\u2013198, doi:10.1016\/j.cca.2015.09.029 (2015).","journal-title":"Clin Chim Acta"},{"key":"5664_CR32","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.neulet.2007.11.048","volume":"431","author":"K Takayama","year":"2008","unstructured":"Takayama, K., Iwazaki, H., Hirabayashi, M., Yakabi, K. & Ro, S. Distribution of c-Fos immunoreactive neurons in the brain after intraperitoneal injection of apelin-12 in Wistar rats. Neurosci Lett \n                           431, 247\u2013250, doi:10.1016\/j.neulet.2007.11.048 (2008).","journal-title":"Neurosci Lett"},{"key":"5664_CR33","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.neuroscience.2016.08.013","volume":"334","author":"J Shen","year":"2016","unstructured":"Shen, J. et al. Omega-3 fatty acid supplement prevents development of intracranial atherosclerosis. Neuroscience \n                           334, 226\u2013235, doi:10.1016\/j.neuroscience.2016.08.013 (2016).","journal-title":"Neuroscience"},{"key":"5664_CR34","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.neulet.2014.03.037","volume":"568","author":"Y Yang","year":"2014","unstructured":"Yang, Y. et al. Apelin-13 protects the brain against ischemia\/reperfusion injury through activating PI3K\/Akt and ERK1\/2 signaling pathways. Neurosci Lett \n                           568, 44\u201349, doi:10.1016\/j.neulet.2014.03.037 (2014).","journal-title":"Neurosci Lett"},{"key":"5664_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vph.2015.08.005","volume":"76","author":"V Novakova","year":"2016","unstructured":"Novakova, V., Sandhu, G. S., Dragomir-Daescu, D. & Klabusay, M. Apelinergic system in endothelial cells and its role in angiogenesis in myocardial ischemia. Vascul Pharmacol \n                           76, 1\u201310, doi:10.1016\/j.vph.2015.08.005 (2016).","journal-title":"Vascul Pharmacol"},{"key":"5664_CR36","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.peptides.2013.05.006","volume":"46","author":"Y Azizi","year":"2013","unstructured":"Azizi, Y., Faghihi, M., Imani, A., Roghani, M. & Nazari, A. Post-infarct treatment with [Pyr1]-apelin-13 reduces myocardial damage through reduction of oxidative injury and nitric oxide enhancement in the rat model of myocardial infarction. Peptides \n                           46, 76\u201382, doi:10.1016\/j.peptides.2013.05.006 (2013).","journal-title":"Peptides"},{"key":"5664_CR37","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1177\/1747493016662039","volume":"11","author":"OY Bang","year":"2016","unstructured":"Bang, O. Y. et al. Caveolin-1, Ring finger protein 213, and endothelial function in Moyamoya disease. Int J Stroke \n                           11, 999\u20131008, doi:10.1177\/1747493016662039 (2016).","journal-title":"Int J Stroke"},{"key":"5664_CR38","doi-asserted-by":"publisher","first-page":"2","DOI":"10.5853\/jos.2015.01627","volume":"18","author":"JS Kim","year":"2016","unstructured":"Kim, J. S. Moyamoya Disease: Epidemiology, Clinical Features, and Diagnosis. J Stroke \n                           18, 2\u201311, doi:10.5853\/jos.2015.01627 (2016).","journal-title":"J Stroke"},{"key":"5664_CR39","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/j.1468-1331.2004.00959.x","volume":"12","author":"T Uehara","year":"2005","unstructured":"Uehara, T., Tabuchi, M. & Mori, E. Risk factors for occlusive lesions of intracranial arteries in stroke-free Japanese. Eur J Neurol \n                           12, 218\u2013222, doi:10.1111\/j.1468-1331.2004.00959.x (2005).","journal-title":"Eur J Neurol"},{"key":"5664_CR40","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S0140-6736(13)61088-0","volume":"383","author":"AI Qureshi","year":"2014","unstructured":"Qureshi, A. I. & Caplan, L. R. Intracranial atherosclerosis. Lancet \n                           383, 984\u2013998, doi:10.1016\/S0140-6736(13)61088-0 (2014).","journal-title":"Lancet"},{"key":"5664_CR41","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s12199-012-0299-1","volume":"18","author":"A Koizumi","year":"2013","unstructured":"Koizumi, A. et al. P.R4810K, a polymorphism of RNF213, the susceptibility gene for moyamoya disease, is associated with blood pressure. Environ Health Prev Med \n                           18, 121\u2013129, doi:10.1007\/s12199-012-0299-1 (2013).","journal-title":"Environ Health Prev Med"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-05664-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-05664-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-05664-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T06:41:42Z","timestamp":1671777702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-05664-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,14]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["5664"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-05664-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,14]]},"assertion":[{"value":"5 December 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"5452"}}